Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades HubSpot to Perform, Announces $375 Price Target

Oppenheimer Downgrades HubSpot to Perform, Announces $375 Price Target

Oppenheimer analyst Ken Wong downgrades HubSpot (NYSE:HUBS) from Outperform to Perform and announces $375 price target.

byBenzinga Newsdesk

November 3, 2022

1 minute read

Oppenheimer analyst Ken Wong downgrades HubSpot (NYSE:HUBS) from Outperform to Perform and announces $375 price target.

Oppenheimer Maintains Underweight on Redfin, Raises Price Target to $7

By Benzinga Newsdesk

February 17, 10:50 AM

Oppenheimer analyst Jason Helfstein maintains Redfin (NASDAQ:RDFN) with a Underweight and raises the price target from $3.2 to $7.

RDFN

Amgen’s Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren’s Syndrome

By Vandana Singh

November 8, 12:43 PM

Amgen Inc (NASDAQ: AMGN) released new

AMGN

Why Ensysce Biosciences Stock Is Exploding Higher During Wednesday’s Session

By Henry Khederian

January 25, 4:58 PM

Ensysce Biosciences Inc (NASDAQ: ENSC) shares are trading higher by 21.81% to $0.82 Wednesday after the company announced initiation of the final stage of its opioid overdose protection Phase 1 study. What Else?

ENSC

News

Why KE Holdings (BEKE) Stock Is Falling

By Henry Khederian

September 25, 12:49 PM

KE Holdings Inc - ADR (NYSE: BEKE) shares are trading lower by 3.8% to $15.74 Monday afternoon.

BEKE

Oppenheimer Downgrades HubSpot to Perform, Announces $375 Price Target

Related Posts

Oppenheimer Maintains Underweight on Redfin, Raises Price Target to $7

Amgen’s Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren’s Syndrome

Why Ensysce Biosciences Stock Is Exploding Higher During Wednesday’s Session

Why KE Holdings (BEKE) Stock Is Falling